Citations

Clear

479 citation(s) found for "Tobias, JS".

004 Convective Radiofrequency Thermal Therapy (Rezum®) Effectively Treats Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Regardless of Obesity while Preserving Erectile and Ejaculatory Function
Köhler, Tobias , McVary, Kevin T. , Helo, Sevann , Tadros, Nicholas N. , Gupta, N.

Mayo Clinic

The Journal of Sexual Medicine | February 3, 2018 | Volume: 15 | Issue: Supplement_1 | Pages: S2-S3

10.1016/j.jsxm.2017.11.023 Get It

Vagal innervation modulates motor pattern but not initiation of canine gastric migrating motor complex
Kendrick, Michael L. , Zyromski, Nicholas J. , Meile, Tobias, Sarr, Michael G., Tanaka, Toshiyuki T.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | December 24, 2017 | Volume: 281 | Issue: 1 | Pages: G283-G292

10.1152/ajpgi.2001.281.1.g283 | PMID 11408282 Get It

To determine the role of vagal nerves in initiation and modulation of the gastric migrating motor complex (MMC), motor activity was recorded in four dogs before and after total abdominal vagotomy during fasting, after exogenous intravenous motilin and insulin, and after feeding. After vagotomy, a temporally coordinated cyclic gastric and small bowel MMC persisted with an unchanged period. During gastric phase III, vagotomy decreased number of contractions (42 ± 4 vs. 16 ± 2), number of groupings of contractions (14 ± 1 vs. 7 ± 1), and motility index (12 ± 1 vs. 10 ± 1) and increased the duration between groupings (1 ± 1 vs. 3 ± 1 min) ( P< 0.05 in each). Before and after vagotomy, motilin and insulin induced a premature MMC with minor changes in contractile pattern. A 200-g liver meal but not a 50-g liver meal inhibited the gastric MMC after vagotomy. A cyclic MMC persisted after vagotomy, but the contractile pattern during gastric phase III was altered. After a short recovery period, vagal innervation to the stomach modulates the pattern but not the presence of gastric interdigestive motility during phase III.
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
Lagares, David , Santos, Alba , Grasberger, Paula , Liu, Fei , Probst, Clemens K. , Rahimi, Rod A. , Sakai, Norihiko , Kuehl, Tobias, Ryan, Jeremy , Bhola, Patrick , Montero, Joan , Kapoor, Mohit , Varelas, Xaralabos , Tschumperlin, Daniel J. , Letai, Anthony , Tager, Andrew M. , Grasberger, Paula E , Baron, Murray , Tschumperlin, Daniel J , Lagares, David , Varelas, Xaralabos , Ryan, Jeremy

Mayo Clinic

Science Translational Medicine | December 13, 2017 | Volume: 9 | Issue: 420 | Pages: No page available

10.1126/scitranslmed.aal3765 | PMID 29237758 Get It

ABT-263 blocks BCL-X L to induce apoptosis in human dermal fibroblasts from patients with scleroderma and in myofibroblasts in mice, reversing dermal fibrosis.
Editorial Comment
Köhler, Tobias

Mayo Clinic

Journal of Urology | November 20, 2017 | Volume: 199 | Issue: 3 | Pages: 810-811

10.1016/j.juro.2017.10.047 | PMID 29154768 Get It

Clinical Factors Negatively Impacting Sexual Relationships in Men With Peyronie's Disease
Ziegelmann, Matthew , Alom, Manaf, Hebert, Kevin , Avant, Ross, Köhler, Tobias , Trost, Landon , Ziegelmann, Matthew J, Hebert, Kevin J

Mayo Clinic

Journal of Sex & Marital Therapy | November 16, 2017 | Volume: 44 | Issue: 5 | Pages: 468-474

10.1080/0092623x.2017.1405312 | PMID 29144850 Get It

Historical epidemiology of hepatitis C virus in select countries—volume 4
Vince, Adriana , Himatt, Sayed , Mohamed, Rosmawati , Opare‐Sem, Ohene , Workneh, A., Njouom, Richard , Ghazzawi, Imad, Abdulla, Maheeba , Kaliaskarova, Kulpash , Owusu‐Ofori, Shirley , Abdelmageed, Marwa , Adda, Danjuma, Baqali, A. Al, Dweik, N. Al, Ejji, Khalid Al, Kaabi, S. Al, Naamani, Khalid Al , Qamish, Jehad Al, Sadadi, M. Al, Salman, Jameela Al , AlBadri, M., Al‐Busafi, Said A. , Al‐Romaihi, Hamad Eid , Ampofo, William , Antonov, Krasimir , Anyaike, Chukwuma , Arome, F., Bane, Abate, Borodo, M. M., Brandon, S., Bright, Bisi , Butt, M. T., Cardenas, I., Chan, Henry Lik‐Yuen , Chen, C. J., Chen, Ding‐Shinn , Chen, Pei‐Jer , Cuellar, Diego , Derbala, M., Elbardiny, A. A., Estes, Chris , Farag, E., Gamkrelidze, Ivane , Garcìa, V. , Genov, J, Ghandour, Z., Ghuloom, M., Gómez, B. , Gunter, J., Habeeb, J., Hajelssedig, O. , Hamoudi, Waseem , Hrstić, Irena , Hu, Ching‐Chih , Huang, Chung‐Feng , Hui, Yee Tak , Jahis, Rohani, Jelev, Deian, John, Anil K , Kamel, Yasser , Kao, Jia‐Horng , Khamis, Jawad, Khattabi, H., Khoudri, Ibtissam , Конысбекова, А А , Kotzev, Iskren, Lai, Moon Sing, Lao, Wenyu, Layden, Jennifer E. , Lee, M. H., Lesi, Olufunmilayo , Li, M., Loo, Ching‐kong, Lukšić, Boris, Malu, Abraham O., Mateva, Lyudmila, Mitova, R, Morović, Miro, Murphy, K., Mustapha, B., Nde, H. , Nersesov, Alexander , Ngige, Evelyn, Njoya, Oudou, Nonković, Diana , Obekpa, Solomon, Oguche, Stephen , Okolo, Eucharia, Omede, O. , Omuemu, C., Phillips, Richard Odame , Prokopenko, Yuriy , Razavi, Homie , Razavi‐Shearer, Devin , Redae, Berhane, Reić, Tatjana, Wit, Tobias Rinke de, Ríos, Cielo , Robbins, S., Roberts, Lewis R. , Sanad, S. J., Schmelzer, Jonathan, Sharma, Manik , Simonova, Marieta, Su, Tung‐Hung , Sultan, K., Tan, S. S. , Tchernev, К., Tsang, O. T. Y., Tsang, S., Tzeuton, Christian, Ugoeze, S., Vi, R., Wani, Hamid, Yacoub, R., Yesmembetov, Kakharman, Youbi, M., Razavi‐Shearer, Kathryn , Wong, Grace Lai‐Hung , Roberts, Lewis R , Fung, James , Akın, Onur , Blach, Sarah , Chien, Rong‐Nan , Chuang, Wan‐Long , Lee, M.-H., Lo, Acy , Ondoa, Pascale , Wit, Tobias F. Rinke de , Robbins, S., Uzochukwu, Benjamin S C. , Wong, Vincent Wai‐Sun , Yuen, Man‐Fung , Lai-Hung Wong, Grace

Mayo Clinic

Journal of Viral Hepatitis | November 4, 2017 | Volume: 24 | Issue: S2 | Pages: 8-24

10.1111/jvh.12762 | PMID 29105285 Get It

SummaryDue to the introduction of newer, more efficacious treatment options, there is a pressing need for policy makers and public health officials to develop or adapt national hepatitis C virus (HCV) control strategies to the changing epidemiological landscape. To do so, detailed, country‐specific data are needed to characterize the burden of chronic HCV infection. In this study of 17 countries, a literature review of published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates was conducted, and inputs were validated by expert consensus in each country. Viraemic prevalence in this study ranged from 0.2% in Hong Kong to 2.4% in Taiwan, while the largest viraemic populations were in Nigeria (2 597 000 cases) and Taiwan (569 000 cases). Diagnosis, treatment and liver transplant rates varied widely across the countries included in this analysis, as did the availability of reliable data. Addressing data gaps will be critical for the development of future strategies to manage and minimize the disease burden of hepatitis C.
The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4
Chan, Henry Lik‐Yuen , Chen, C. J., Omede, O. , Qamish, Jehad Al, Naamani, Khalid Al , Bane, Abate, Tan, S. S. , Simonova, Marieta, Cardenas, I., Derbala, Moutaz , Phillips, Richard Odame , Abdelmageed, Marwa , Abdulla, Maheeba , Adda, Danjuma, Baqali, A. Al, Dweik, N. Al, Ejji, Khalid Al, Ghazzawi, Imad, Kaabi, S. Al, Sadadi, M. Al, Salman, Jameela Al , AlBadri, M., Al‐Busafi, Said A. , Al‐Romaihi, Hamad Eid , Ampofo, William , Antonov, Krasimir , Anyaike, Chukwuma , Arome, F., Blach, Sarah , Borodo, M. M., Brandon, S., Bright, Bisi , Butt, M. T., Chen, Ding‐Shinn , Chen, Pei‐Jer , Cuellar, Diego , Elbardiny, A. A., Farag, Elmoubasher , Gamkrelidze, Ivane , Garcìa, V. , Genov, J, Ghandour, Z., Ghuloom, M., Gómez, B. , Gunter, J., Habeeb, J., Hajelssedig, O. , Hamoudi, Waseem , Himatt, Sayed , Hrstić, Irena , Hu, Ching‐Chih , Huang, Chung‐Feng , Hui, Yee Tak , Jahis, Rohani, Jelev, Deian, John, Anil K , Kaliaskarova, Kulpash , Kamel, Yasser , Kao, Jia‐Horng , Khamis, Jawad, Khattabi, H., Khoudri, Ibtissam , Конысбекова, А А , Kotzev, Iskren, Lai, Moon Sing, Lao, Wenyu, Layden, Jennifer E. , Lee, M. H., Lesi, Olufunmilayo , Li, M., Loo, Ching Kong, Lukšić, Boris, Maaroufi, Abderrahmane , Malu, Abraham O., Mateva, Lyudmila, Mitova, R, Mohamed, Rosmawati , Morović, Miro, Murphy, K., Mustapha, B., Nersesov, Alexander , Ngige, Evelyn, Njouom, Richard , Njoya, Oudou, Nonković, Diana , Obekpa, Solomon, Oguche, Stephen , Okolo, Eucharia, Omuemu, C., Opare‐Sem, Ohene , Owusu‐Ofori, Shirley , Prokopenko, Yuriy , Razavi, Homie , Razavi‐Shearer, Devin , Razavi‐Shearer, Kathryn , Redae, Berhane, Reić, Tatjana, Wit, Tobias Rinke de, Ríos, Cielo , Robbins, S., Roberts, Lewis R. , Sanad, S. J., Schmelzer, Jonathan, Sharma, Manik , Su, Tung‐Hung , Sultan, K., Tchernev, К., Tsang, O. T. Y., Tsang, Simon H. Y., Tzeuton, Christian, Ugoeze, S., Vi, R., Vince, Adriana , Wani, Hamid, Workneh, A., Yacoub, R., Yesmembetov, Kakharman, Youbi, M., Nde, H. , Wong, Grace Lai‐Hung , Blach, S , Roberts, Lewis R , Akın, Onur , Chien, Rong‐Nan , Chuang, Wan‐Long , Estes, Chris , Fung, James , Lee, M.-H., Lo, Acy , Ondoa, Pascale , Wit, Tobias F. Rinke de , Robbins, S., Uzochukwu, Benjamin S C. , Wong, Vincent Wai‐Sun , Yuen, Man‐Fung , Lai-Hung Wong, Grace

Mayo Clinic

Journal of Viral Hepatitis | November 4, 2017 | Volume: 24 | Issue: S2 | Pages: 25-43

10.1111/jvh.12760 | PMID 29105283 Get It

SummaryFactors influencing the morbidity and mortality associated with viremic hepatitis C virus (HCV) infection change over time and place, making it difficult to compare reported estimates. Models were developed for 17 countries (Bahrain, Bulgaria, Cameroon, Colombia, Croatia, Dominican Republic, Ethiopia, Ghana, Hong Kong, Jordan, Kazakhstan, Malaysia, Morocco, Nigeria, Qatar and Taiwan) to quantify and characterize the viremic population as well as forecast the changes in the infected population and the corresponding disease burden from 2015 to 2030. Model inputs were agreed upon through expert consensus, and a standardized methodology was followed to allow for comparison across countries. The viremic prevalence is expected to remain constant or decline in all but four countries (Ethiopia, Ghana, Jordan and Oman); however, HCV‐related morbidity and mortality will increase in all countries except Qatar and Taiwan. In Qatar, the high‐treatment rate will contribute to a reduction in total cases and HCV‐related morbidity by 2030. In the remaining countries, however, the current treatment paradigm will be insufficient to achieve large reductions in HCV‐related morbidity and mortality.
Strategies to manage hepatitis C virus infection disease burden—Volume 4
Chen, Ding‐Shinn , Hamoudi, Waseem , Mustapha, B., Layden, Jennifer E. , Nersesov, Alexander , Reić, Tatjana, Garcìa, V. , Ríos, Cielo , Mateva, Lyudmila, Njoya, Oudou, Al‐Busafi, Said A. , Abdelmageed, Marwa , Abdulla, Maheeba , Adda, Danjuma, Baqali, A. Al, Dweik, N. Al, Ejji, Khalid Al, Ghazzawi, Imad, Kaabi, S. Al, Naamani, Khalid Al , Qamish, Jehad Al, Sadadi, M. Al, Salman, Jameela Al , AlBadri, M., Al‐Romaihi, Hamad Eid , Ampofo, William , Antonov, Krasimir , Anyaike, Chukwuma , Arome, F., Bane, Abate, Blach, Sarah , Borodo, M. M., Brandon, S., Bright, Bisi , Butt, M. T., Cardenas, I., Chan, Henry Lik‐Yuen , Chen, C. J., Chen, Pei‐Jer , Cuellar, Diego , Derbala, M., Elbardiny, A. A., Farag, E., Gamkrelidze, Ivane , Genov, J, Ghandour, Z., Ghuloom, M., Gómez, B. , Gunter, J., Habeeb, J., Hajelssedig, O. , Himatt, Sayed , Hrstić, Irena , Hu, Ching‐Chih , Huang, Chung‐Feng , Hui, Yee‐Tak, Jahis, Rohani, Jelev, Deian, John, Anil K , Kaliaskarova, Kulpash , Kamel, Yasser , Kao, Jia‐Horng , Khamis, Jawad, Khattabi, H., Khoudri, Ibtissam , Конысбекова, А А , Kotzev, Iskren, Lai, Moon Sing, Lao, Wenyu, Lee, M. H., Lesi, Olufunmilayo , Li, M., Loo, Ching‐kong, Lukšić, Boris, Maaroufi, Abderrahmane , Malu, Abraham O., Mitova, R, Mohamed, Rosmawati , Morović, Miro, Murphy, K., Nde, H. , Ngige, Evelyn, Njouom, Richard , Nonković, Diana , Obekpa, Solomon, Oguche, Stephen , Okolo, Eucharia, Omede, O. , Omuemu, C., Opare‐Sem, Ohene , Owusu‐Ofori, Shirley , Phillips, Richard Odame , Prokopenko, Yuriy , Razavi, Homie , Razavi‐Shearer, Devin , Razavi‐Shearer, Kathryn , Redae, Berhane, Wit, Tobias Rinke de, Robbins, S., Roberts, Lewis R. , Sanad, S. J., Sharma, Manik , Simonova, Marieta, Su, Tung‐Hung , Sultan, K., Tan, S. S. , Tchernev, К., Tsang, O. T. Y., Tsang, Simon H. Y., Tzeuton, Christian, Ugoeze, S., Vi, R., Vince, Adriana , Wani, Hamid, Workneh, A., Yacoub, R., Yesmembetov, Kakharman, Youbi, M., Schmelzer, Jonathan, Hui, Yee Tak , Wong, Grace Lai‐Hung , Blach, S , Roberts, Lewis R , Akın, Onur , Chien, Rong‐Nan , Chuang, Wan‐Long , Estes, Chris , Fung, James , Lee, M.-H., Lo, Acy , Ondoa, Pascale , Wit, Tobias F. Rinke de , Robbins, S., Uzochukwu, Benjamin S C. , Wong, Vincent Wai‐Sun , Yuen, Man‐Fung , Lai-Hung Wong, Grace

Mayo Clinic

Journal of Viral Hepatitis | November 4, 2017 | Volume: 24 | Issue: S2 | Pages: 44-63

10.1111/jvh.12759 | PMID 29105286 Get It

SummaryThe hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global Health Sector Strategy on viral hepatitis targets—“WHO Targets” (65% reduction in HCV‐related deaths, 90% reduction in new infections and 90% of infections diagnosed by 2030) were considered. Scaling up treatment and diagnosis rates over time would be required to achieve these targets in all but one country, even with the introduction of high SVR therapies. The scenarios developed to achieve the WHO Targets in all countries studied assumed the implementation of national policies to prevent new infections and to diagnose current infections through screening.
The impact of hypsarrhythmia on infantile spasms treatment response: Observational cohort study from the National Infantile Spasms Consortium
Demarest, Scott , Shellhaas, Renée A. , Gaillard, William D. , Keator, Cynthia, Nickels, Katherine , Loddenkemper, Tobias , Saneto, Russell P. , Fernández, Iván Sánchez , Chu, Catherine J. , Wusthoff, Courtney J. , Joshi, Sucheta M. , Mohamed, Ismail , Stafstrom, Carl E. , Stack, Cynthia V. , Yozawitz, Elissa , Bluvstein, Judith , Singh, Rani K. , Demarest, Scott T , Shellhaas, Renée A , Gaillard, William D , Loddenkemper, Tobias , Yozawitz, Elissa G , Chu, Catherine J , Nickels, Katherine C , Hussain, Shaun A. , Patel, Anup D. , Wirrell, Elaine , Grinspan, Zachary M. , Knupp, Kelly G. , Wusthoff, Courtney J

Mayo Clinic

Epilepsia | November 3, 2017 | Volume: 58 | Issue: 12 | Pages: 2098-2103

10.1111/epi.13937 | PMID 29105055 Get It

SummaryObjectiveThe multicenter National Infantile Spasms Consortium prospective cohort was used to compare outcomes and phenotypic features of patients with infantile spasms with and without hypsarrhythmia.MethodsPatients aged 2 months to 2 years were enrolled prospectively with new‐onset infantile spasms. Treatment choice and categorization of hypsarrhythmia were determined clinically at each site. Response to therapy was defined as resolution of clinical spasms (and hypsarrhythmia if present) without relapse 3 months after initiation.ResultsEighty‐two percent of patients had hypsarrhythmia, but this was not associated with gender, mean age, preexisting developmental delay or epilepsy, etiology, or response to first‐line therapy. Infants with hypsarrhythmia were more likely to receive standard treatment (adrenocorticotropic hormone, prednisolone, or vigabatrin [odds ratio (OR) 2.6, 95% confidence interval (CI) 1.4–4.7] and preexisting epilepsy reduced the likelihood of standard treatment (OR3.2, 95%CI1.9–5.4). Hypsarrhythmia was not a determinant of response to treatment. A logistic regression model demonstrated that later age of onset (OR1.09 per month, 95%CI1.03–1.15) and absence of preexisting epilepsy (OR1.7, 95%CI1.06–2.81) had a small impact on the likelihood of responding to the first‐line treatment. However, receiving standard first‐line treatment increased the likelihood of responding dramatically: vigabatrin (OR5.2 ,95%CI2–13.7), prednisolone (OR8, 95%CI3.1–20.6), and adrenocorticotropic hormone (ACTH;OR10.2, 95%CI4.1–25.8) .SignificanceFirst‐line treatment with standard therapy was by far the most important variable in determining likelihood of response to treatment of infantile spasms with or without hypsarrhythmia.